Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KarXT in Psychosis Associated With Alzheimer's Disease
NCT06126224Phase 3Recruiting
- Sponsor
- Karuna Therapeutics
- Start
- Aug 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 14
01
Overview
Phase 3, randomised, double-blind trial in Alzheimer's disease psychosis (ADP) comparing KarXT with Placebo (2 arms). Primary endpoint: Neuropsychiatric Inventory-Clinician: Hallucinations and Delusions score at 14 weeks. Started Aug 2023; status: recruiting.
02
Drugs
xanomeline
03
Conditions
Alzheimer's disease psychosis (ADP)
Beyond the preview
Go deeper on NCT06126224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06126224.